Cargando…
SAT-180 Adrenocortical Carcinoma - A Tertiary Center’s Recent 5-Year Experience
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis. The aim of this study was to characterize patients diagnosed with ACC at a single center between 2014-2019. METHODS: We retrospectively reviewed data regarding demographics, tumor characteristics and funct...
Autores principales: | Ehrenwald, Michal, Tordjman, Karen Michele, Stern, Naftali, Klausner, Joseph, Nachmany, Ido, Lahat, Guy, Lubezky, Nir, Goykhman, Yaakov, Wolf, Ido, Geva, Ravit, Aizic, Asaf, Barnes, Sophie, Greenman, Yona, Osher, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207697/ http://dx.doi.org/10.1210/jendso/bvaa046.1015 |
Ejemplares similares
-
MON-194 Phaeochromocytoma-Paraganglioma (PPGL): Post-Operative Hypotension Is a Vanishing Phenomenon
por: Osher, Esther, et al.
Publicado: (2020) -
Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity
por: Osher, Esther, et al.
Publicado: (2023) -
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
por: Osher, Esther, et al.
Publicado: (2023) -
Early reoperation following pancreaticoduodenectomy: impact on morbidity, mortality, and long-term survival
por: Lessing, Yonatan, et al.
Publicado: (2019) -
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)